Cor Vasa 2012, 54(1-2):e39-e44 | DOI: 10.1016/j.crvasa.2011.12.003

Management of hypertrophic obstructive cardiomyopathy with a focus on interventional therapy

Josef Veselka
Kardiologická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Motol, Praha, Česká republika

Keywords: Alkoholová septální ablace; Hypertrofická kardiomyopatie; Obstrukce

Received: December 15, 2011; Accepted: December 30, 2011; Published: January 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Veselka J. Management of hypertrophic obstructive cardiomyopathy with a focus on interventional therapy. Cor Vasa. 2012;54(1-2):e39-44. doi: 10.1016/j.crvasa.2011.12.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Elliott P, Anderson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6. Go to original source... Go to PubMed...
    2. Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature. Med Sci Monit 2007;13:RA62-8. Go to original source...
    3. McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-71. Go to original source...
    4. Gilgenkrantz J, Cherrier F, Petitier H, Dodinot B, Houplon M, Legoux J. Cardiomyopathie obstructive du ventricle gauche avec block auriculo-ventriculaire complet. Considerations therapeutiques. Arch Mal Coeur 1968;61:439-53.
    5. Linde C, Gadler F, Kappenberger L, et al. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol 1999;83:903-7. Go to original source...
    6. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-33. Go to original source...
    7. Nishimura RA, Trusty J, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomised, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435-41. Go to original source...
    8. Sigwart U, Grbie M, Essinger A, Rivier JL. L'effet aigu d'une occlusion coronarienne par ballonet de la dilatation transluminale. Schweiz Med Wochenschr 1982;45:1631.
    9. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4. Go to original source...
    10. Kuhn HJ. The history of alcohol septal ablation. Cardiovasc Revasc Med 2010;11:260-1. Go to original source... Go to PubMed...
    11. Veselka J, Zemánek D, Fiedler J, Šváb P. Real-time myocardial contrast echocardiography for echo-guided alcohol septal ablation. Arch Med Sci 2009;5:271-2.
    12. Veselka J, Duchoňová R, Procházková Š, Páleníčková J, Sorajja P, Tesař D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005;95:675-8. Go to original source... Go to PubMed...
    13. Veselka J, Zemánek D, Tomašov P, Homolová S, Adlová R, Tesař D. Complications of low-dose echo-guided alcohol septal ablation. Catheter Cardiovasc Interv 2010;75:546-50. Go to original source... Go to PubMed...
    14. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 2008;97:234-43. Go to original source... Go to PubMed...
    15. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 2007;96:864-73. Go to original source... Go to PubMed...
    16. Veselka J, Tomašov P, Zemánek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol 2011;27:763-7. Go to original source... Go to PubMed...
    17. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 2011;75:28-37. Go to original source... Go to PubMed...
    18. Veselka J, Duchoňová R, Procházková Š, Homolová I, Páleníčková J, Zemánek D, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;60:133-5. Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes